Portable Continuous Wave Doppler Ultrasound for Primary Healthcare in South Africa: Can the EUnetHTA Core Model Guide Evaluation Before Technology Adoption?

Debjani Mueller (dbmueller7@yahoo.de)
Department of Health Care Management, Berlin University of Technology, Berlin, Germany
Charlotte Maxeke Research Cluster, Johannesburg, South Africa
https://orcid.org/0000-0001-7796-982X

Robert C Pattinson
University of Pretoria Faculty of Health Sciences

Tsakane Musa Hlongwane
University of Pretoria Faculty of Health Sciences

Reinhard Busse
Technische Universitat Berlin

Dimitra Panteli
Technische Universitat Berlin

Research

Keywords: Health Technology Assessment, Doppler ultrasound, South Africa

DOI: https://doi.org/10.21203/rs.3.rs-67699/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: This study had a threefold aim: to test the value of stakeholder involvement in HTA to reduce the evidence gaps and interpret findings; applicability of the EUnetHTA Core Model (CM) in South Africa on a medical device and thus ultimately provide a first overview of evidence for potential widespread adoption of the technology in a primary health care setting. Used in primary healthcare setting for obstetric use, the technology under assessment is a low-cost continuous wave Doppler ultrasound.

Methods: To substantiate the evidence obtained from the literature different stakeholders were identified and consulted. The scoping of the assessment was defined by involving the policy makers to select the domains and the analogous questions relevant to the ultrasound and its use. Additionally, hospital managers were invited to respond to dichotomous questions on the criteria for procurement. The evidence generated from the four steps was used to populate the high-ranked assessment elements of the CM.

Results: The HTA took into account the clinical benefit in screening low-risk pregnant women in primary healthcare settings using the technology. It incorporated the evidence on organizational, ethical, and social value of its use together with effectiveness, safety, and cost-effectiveness of the technology. The domains on “health problem” and “safety” had a higher rank than the rest of the nine domains.

Conclusions: A multi-stakeholder participation in the assessment process provided the necessary transparency and accountability, thus improving the quality of the recommendation resulting from the assessment. The collection of robust evidence and analysis post-introduction will enable the determination of the value of the technology in real-world settings.

Background

Globally, maternal and child mortality remain unacceptably high, despite significant progress in recent years [1]; reducing them remains a priority for many governments. Particularly in sub-Saharan Africa (SSA), access to adequate essential reproductive health services remains one of the challenges towards achieving universal health coverage (UHC). Maternal mortality amounted to 533 deaths per 100000 live births in 2017, compared to 11 deaths per 100000 live births among high-income countries and 211 deaths per 100000 live births globally [2]. The third-trimester stillbirth rate in SSA is approximately 10 times higher than in developed countries – 29 vs 3 per 1000 births [3]. The Every Newborn Action Plan to end preventable deaths, endorsed by the United Nations member states at the World Health Assembly in 2014, set a stillbirth target of 12 per 1000 births or less by 2030. SSA countries are still far from achieving this goal [3].

In many resource-poor settings, the availability and quality of care in health facilities are not sufficient to hinder adverse maternal or fetal outcomes [4, 5]. While the use of conventional ultrasound diagnostics is a routine component of antenatal care in high-income countries, in many low- and middle-income...
countries (LMICs), the only way to determine fetal growth rate at the primary care level is by palpation and measuring the symphysis fundal height (SFH) using tape measure [6]. Small studies in LMICs have shown that the use of the conventional ultrasound directly influences antenatal care (ANC) utilization, improving referral for detected conditions and gestational age dating, and increasing the use of hospital for deliveries [7]. However, Goldenberg et al [7] in their cluster randomized trial, concluded that routine conventional ultrasound found no effect on ANC attendance, reduction in maternal, stillbirth or neonatal mortality. Furthermore, it seems to contribute to the improvement of patient management and the confirmation of clinically suspected obstetric complications [8]. The potential impact of routine ultrasound use in LMICs where perinatal and maternal mortality rates are high, and access to and quality of antenatal care are poor [7, 9] can be significant. The Doppler ultrasound (DUS), a specific type of ultrasound detects changes in the pattern of fetal blood flow in the umbilical artery [10]. Continuous-wave Doppler, a type of DUS is relatively inexpensive, easier to use and has lower energy output than pulsed-wave DUS. However, continuous wave Doppler does not provide precise depth information. This can be mitigated by using pulsed Doppler instruments, which has the capability of depth resolution and measuring a variable sample volume. It is however, more costly and requires trained sonographers. A Cochrane systematic review of the application of the DUS in high-risk pregnancies suggests that its use can decrease the risk of perinatal death resulting in fewer obstetric interventions [11].

A system-based approach focusing on improving the quality of care in health facilities and ensuring the delivery of essential healthcare services is necessary to reduce maternal and perinatal mortality in LMICs [12]. In South Africa, primary healthcare (PHC) is offered free of charge to the population by the state [13], while all health services are free of charge for pregnant women and children under the age of six. The district health system, divided into 52 health districts, is the government's mechanism to facilitate and strengthen the delivery of primary care and district hospital services [14]. District and sub-district Management Teams and hospital Chief Executive Officers (CEOs) are responsible for services at communities and facilities in their districts [15]. In this capacity, they have to ensure that safe, effective, and essential technologies are procured and maintained within their respective budgets. Indeed, while the public health sector accounts for about 40% of all expenditure on health, it is under pressure to deliver services to about 80% of the population [16]. Inequalities exist in the distribution of hospitals between provinces and rural settings, with healthcare workers being disproportionately employed in the private sector [13]. It was therefore essential to consider options for improving ANC that would reflect the limited overall resources in the public health system (financial and professional) and the need for flexibility to address the unequal distribution of services in the country.

With this in mind, the South African Medical Research Council (SAMRC), Tygerberg Research Unit in Cape Town, and Centre for Scientific and Industrial Research (CSIR) developed a novel portable continuous-wave DUS, the Umbiow™, to be used in remote areas and PHC settings. Currently, the technology is undergoing CE tests for market access, and in collaboration with World Health Organization (WHO), is tested in various cohort studies in South Africa and abroad.
Health Technology Assessment (HTA) is used to evaluate the potential for adoption of the Umbiflow™ technology. HTA enables evidence-based decision-making on the introduction and use of safe, effective, and efficient technologies at various levels of the healthcare system. Its methodology has been developed substantially over the past twenty years; for instance, the European Network for Health Technology Assessment, (EUnetHTA) Core Model™ provides a comprehensive framework for conducting HTA. The Core Model (CM) was developed in the context of co-operation between European countries. It provides a validated and preference-oriented structured methodology for the assessment of health technologies [17]. South Africa, similar to other settings that have recently adopted HTA, does not yet have a methodological guideline to evaluate non-pharmacological technologies. However, the importance of HTA for improving quality and safety of PHC services was also noted at a Presidential Summit on UHC [18] in 2018.

In emerging settings, and especially when the technology under investigation is not yet fully established, it is necessary to consider a broad range of evidence to obtain a full picture of the consequences of the technology's implementation. To increase the acceptance of the HTA findings, involving the relevant stakeholders throughout the HTA process is beneficial, beginning with the scoping of the assessment [19, 20].

This study aims to:

a. test the applicability of the EUnetHTA Core Model to evaluate a technology at an earlier stage of adoption at a non-European setting;

b. demonstrate the value of stakeholder engagement and consultation to mitigate evidence gaps, address uncertainties, and interpret findings when evaluating technologies in an emerging setting with limited resources;

c. Provide a first overview of evidence for the potential widespread adoption of Umbiflow™ in PHC in South Africa.

**Methods**

The CM, which enables integration of various dimensions of a technology (Fig. 1) and the impact of its use, was chosen to guide a stakeholder-based assessment of Umbiflow™. To define the scope of the HTA, district managers responsible for the delivery of primary care services, were invited to rank the relevance of the CM domains and the corresponding questions (Step1) relevant to the technology. A modified survey was developed to establish consensus on the decision criteria used by hospital managers to procure technologies (Step 2). In Step 3, evidence on continuous-wave DUS was collected from the literature and consolidated with the initial search and recommendations arising from Step 4. The initial search accompanied the scoping of the assessment and for formulating the research question. Step 4 involved consultation with clinical and technical experts and collating information on user experience from questionnaires. Each step is described below in more detail.
Step1: Selecting Core Model domains and issues for consideration

Considering that, the application of HTA for medical devices (MDs) at the PHC level in South Africa is nascent, applying a validated standardized HTA methodology for MDs can provide a framework for collecting and synthesizing information and sharing of results [21]. The CM contains issues, topics and domains, which are nested together into assessment elements (AEs). It is a preference-oriented model composed of nine evaluation domains (Fig. 1). Each domain represents “a wide framework within which the assessed technology is considered. It provides an angle of viewing the use, consequence, or implications of using the technology and any other aspects applicable to it” [22]. The domains provide guidance on tools and methods for the systematic identification, analysis, and presentation of information. Each domain is divided into several topics and each topic is further divided into various issues; the latter correspond to specific questions to be examined when assessing a technology [22]. Because of the novelty of using HTA in general, and the CM in particular, CM for evaluating MDs in South Africa and the limitations on data, a prioritization of domains and AEs was undertaken by the decision-makers to identify their perceived evidentiary needs.

District health managers were invited for a workshop on June 6, 2019, at the University of Pretoria to define the scope of HTA for this case study. The Centre for Maternal, Fetal, Newborn and Child Health Care Strategies, University of Pretoria helped to contact and distribute the email invitations to senior managers in Tshwane Health District. Out of the 26 managers invited, 24 participated in the ranking exercise resulting in a response rate of 92.3%. Information on HTA, the CM, and the objective of the assessment was prepared and presented to the managers in advance (2 May 2019). The objective of the workshop was to select and rank the AEs according to the relevance of the evidence needed for informed decisions. One author (DM) and trained researchers from the Centre facilitated the meeting and the ranking exercise. For each domain and AE, a 5-point Likert scale was applied, where “1” was least relevant and “5” was most relevant. Median scores were calculated per choice to characterize the category above and below which 50 percent of the scores fall. Interquartile ranges (IQR) were calculated to evaluate the degree of consensus per choice. Ratings with a median of < = 2 and a narrow IQR (between 1 and 2) were considered to have reached consensus on the least relevant. A median of > = 4 and an IQR between 4 and 5 were considered to be most relevant (see Table 1).
### Table 1
Ranking of HTA Domains and assessment elements

| Element ID | Topic/Issue                                                                 | Median (IQR) | No of responses (%) |
|------------|-------------------------------------------------------------------------------|--------------|---------------------|
| **Health problem and current use of the technology (CUR)** | | | |
| **Target population** | | | |
| A0007 | What is the target population in this assessment? | 5 (4,5) | 24 |
| A0023 | How many people belong to this target population | 5 (3.75, 5) | 24 |
| **Target condition** | | | |
| A0002 | What is the health condition | 5 (4,5) | 24 |
| A0003 | What are the known risk factors? | 5 (4,5) | 24 |
| A0004 | What is the natural course of the health condition? | 4 (4,5) | 23 |
| A0005 | What are the symptoms or health condition for the patient? | 4 (4,5) | 24 |
| A0006 | What are the consequences of the health condition for the society? | 4.5 (4,5) | 22 |
| A0009 | What aspects of the consequences are targeted by the Umbiflow? | 4 (4,5) | 23 |
| **Current management of the condition** | | | |
| A0018 | What are the other typical or common alternatives to the Umbiflow? | 4 (3.5,5) | 23 |
| A0024 | How is the health condition currently diagnosed according to published guidelines and in practice? | 4 (4,5) | 24 |
| A0025 | How is the health condition currently managed according to published guidelines and in practice? | 4 (4,5) | 24 |
| **Utilization** | | | |
| A0001 | For which health conditions and populations, and for what purposes is the technology used? | 4 (3,5) | 24 |
| A0011 | How much are the technologies utilized? | 4 (3,5) | 24 |
| F0001 | Is Umbiflow a new, innovative mode of care, an add-on to, or modification of a standard mode of care, or a replacement of a standard mode of care? | 4 (3,5) | 24 |
| **Description and technical characteristics of technology (TEC)** | | | |
| | | | |
| **Safety (SAF)** | | | |
| | | | |
| Element ID | Topic/Issue                                                                 | Median (IQR) | No of responses (%) |
|------------|------------------------------------------------------------------------------|--------------|---------------------|
| C0006      | What are the consequences of false positive, false negative and incidental findings generated by using the technology from the viewpoint of patient safety? | 4 (3,5)      | 24                  |
|            | **Clinical effectiveness (EFF)**                                             |              |                     |
|            | *Mortality*                                                                  |              |                     |
| D0001      | What is the expected beneficial effect of intervention on mortality?         | 4 (4,5)      | 24                  |
|            | *Morbidity*                                                                  |              |                     |
| D0005      | How does using Umbiow affect findings of the health condition?              | 4 (4,5)      | 24                  |
| D1004      | What are the requirements for accuracy in the context where the technology will be used? | 4 (3,5)      | 24                  |
|            | **Change-in-management**                                                     |              |                     |
| D0020      | Does use of the test lead to improved detection of the condition?           | 4 (4,5)      | 24                  |
| D0010      | How does the technology modify the need for hospitalisation?                | 4 (3,5)      | 24                  |
|            | **Benefit-harm balance**                                                     |              |                     |
| D0029      | What are the overall benefits and harms of the technology in health outcomes? | 4 (3,5)      | 24                  |
|            | **Costs and Economic aspect**                                                |              |                     |
|            | *Process-related costs*                                                      |              |                     |
| G0006      | What are the costs of processes related to acquisition and setting up new technology? | 4 (3,5)      | 23                  |
| G0007      | What are the likely budget impacts of implementing the technology?          | 4 (3,5)      | 23                  |
|            | **Ethical aspect**                                                          |              |                     |
|            | *Autonomy*                                                                   |              |                     |
| F0006      | Is there a need for any specific interventions or supportive actions concerning information in order to respect patient autonomy when the technology is used? | 4 (3.5,5)    | 23                  |
| F0007      | Does the implementation or withdrawal of the technology challenge or change professional values, ethics or traditional roles? | 4 (3,4.5)    | 23                  |
|            | **Legislation**                                                             |              |                     |
| Element ID | Topic/Issue                                                                 | Median (IQR) | No of responses (%) |
|------------|------------------------------------------------------------------------------|--------------|---------------------|
| F0014      | Does the implementation or use of the technology affect the realisation of basic human rights? | 4 (3.5)      | 23                  |
|            | **Organizational aspect**                                                     |              |                     |
| G0001      | How does the technology affect the current work processes?                    | 4 (3.5)      | 24                  |
| G0100      | What kind of patient/participant flow is associated with the new technology?  | 4 (3.5)      | 24                  |
| G0002      | What kind of involvement has to be mobilised for patients/participants and important others and/or caregivers? | 4 (3.5)      | 21                  |
| G0003      | What kind of process ensures proper education and training of staff?          | 4 (3.5)      | 23                  |
|            | **Management**                                                               |              |                     |
| G0008      | What management problems and opportunities are attached to the technology?   | 4 (3.5)      | 24                  |
|            | **Patient and social aspect**                                                |              |                     |
| H0100      | What expectations and wishes do patients have with regard to the technology and what do they expect to gain from the technology? | 4 (3.5)      | 24                  |
|            | **Communication aspects**                                                    |              |                     |
| H0202      | How are treatment choices explained to patients?                             | 4 (3.5)      | 24                  |
|            | **Legal aspect**                                                             |              |                     |
| I0034      | Who is allowed to give consent for minors and incompetent persons?           | 4 (3.5)      | 24                  |
|            | **Autonomy of the patient**                                                  |              |                     |
| I0009      | What do laws/binding rules require with regard to appropriate measures for securing patient data and how should this be addressed when implementing the technology? | 4 (3.75,4.25) | 24                  |

**Step 2: Determining the decision criteria of hospital CEOs**

The CEOs of the hospitals enrolled in cohort studies on Umbiflow™ were invited to identify the decision criteria they considered necessary for technology adoption. While the CM guides data collection and
analysis, it does not extend to ways of translating the assessment results into decisions. In this study, it was envisioned that identifying a set of decision criteria early in the assessment process could ensure that the information needs of the hospital decision-makers are met using best available evidence. The fifteen components of the EVIDEM (Evidence and Value: Impact on DecisionMaking) framework for healthcare decision-making [23] were chosen as the basis. Broadly, these components, which are based on the intrinsic and extrinsic value of healthcare intervention includes need, improvement of outcomes and feasibility of application. To ensure conceptual consistency in the study, the criteria were first juxtaposed with the CM and found not to differ substantially in terms of structure, logic, and content. Currently, cohort trials are ongoing at nine sites in the eight provinces in South Africa. CEOs at the district hospitals in these provinces were asked to agree or disagree with each criterion in the framework (see “Supplementary Table 1a, Additional File 1”).

The principal investigator of the cohort studies (RP) facilitated the distribution of the email invitation. The email included a cover letter inviting the CEOs to participate and described the study objectives and the list of criteria. The invitation stated that the information obtained will be used to prepare guidance towards developing an assessment tool and will be published. Invitations were sent by mail to all nine-study sites; the email communication and collection of responses took place between June and September 2019. Three out of the nine CEOs invited agreed to participate and returned filled-out questionnaires to the authors.

Step 3: Identification of published studies on Umbiflow™ and continuous-wave Doppler ultrasound

While steps 1 and 2 served to define the scope and main principles of the assessment process, steps 3 and 4 aimed to collect evidence targeting Umbiflow™. In Step 3, the following databases were searched using search strategies based on the PICOTS framework delineated below: PubMed (MEDLINE), EMBASE, HTA CRD, and the INAHTA database.

- Population: Target population in these regions – low-risk singleton pregnant patients of > 28 weeks gestation or with symphysis fundal height (SFH) measurement of 26-30cm if gestational age was unknown.
- Intervention: Use of continuous-wave DUS.
- Comparator: No screening using ultrasound
- Outcome: patient-relevant outcomes (e.g. early detection of anomalies; Increase in diagnostic accuracy compared to SFH measurement)
- Time: open to September 2019
- Study types: No restrictions to the type of study

First, published literature on continuous-wave DUS and its assessment was searched using the key words linked with Boolean operators. The search results were screened by one author (DM) and information was extracted from included studies based on a semi-structured information collection guide. After expert
consultation (Step 4), this step 3 was revisited as additional criteria such as “low-risk” AND “third trimester” were included. Further targeted searches were conducted to identify potentially missed literature specifically on the technology’s technical properties, safety aspects, and application. The reference lists of all identified sources were searched for further relevant evidence.

**STEP 4 Collating user experience and expert consultation**

Two authors who are also clinical investigators on Umbiflow (RP and TMH), provided unpublished data, additional literature, and direct expertise to complement the evidence generated by the literature search. The intent was to collate information on technical features, the health problem, and clinical practice using a structured tool (see “Supplementary Table 1c, Additional File 1”).

Furthermore, nurses and clinicians participating in the cohort studies of Umbiflow™ were requested to share their experience. The questionnaire (see “Supplementary Table 1d, Additional File 1”) to the nurses consisted of a section inquiring about their experience of using the DUS and on potential patient benefits and harms. The questionnaire to the clinicians (see “Supplementary Table 1d, Additional File 1”) varied slightly to reflect their expertise and included additional sections on post-introduction management of the technology in comparison to standard care and the potential impact on the system. Both the questionnaires have been adapted from the NICE Medical Technologies Evaluation Program. A first version of the questionnaires was piloted with two clinicians to review coherence and appropriateness of content, language, and format. The refined version was then sent by mail to all study sites between June and September 2019. The research centre facilitated the distribution. During a site visit to one of the health care facilities using Umbiflow™, one of the authors (DM) also gathered information on patient satisfaction indirectly, with the nurse or clinician on duty asking patients about their satisfaction with the screening.

**Results**

Selection of domains and assessment elements under consideration

Twenty-four district health managers from the Tshwane Health District participated in scoring the domains and AEs. One to three managers did not provide scores for some of the criteria. The median, IQR, and the number of responses for each domain and sub-category AEs are presented in Table 1.

The domains on “health problem and current of use of technology” (CUR) and “safety” (SAF) had a median of 5 and the rest of the 9 domains had a median of 4. However, there was a variance observed in the IQR. 5 of the 9 domains including CUR and SAF reached a consensus with a strong agreement (IQR between 4 and 5) on their relevance. In the case of the other domains, the IQR varied between 3 and 5. For instance, managers were uncertain about the necessity of evidence on organizational implications (ORG) and questioned the appropriateness of detailed technical evaluation (TEC).

Variation was also observed across AEs within the individual domains (see Table 1). For instance, the disagreement on the relevance of some of the AEs may stem from the priority given to access to high
quality maternal and child health and the relatively early phase of implementation of the device (cohort studies in different provinces). Similarly, even though the economic impact and affordability were relevant among the decision-makers (median = 4), the managers disagreed widely on the relevancy of individual AEs. This could be due to the feasibility of conducting an economic evaluation based on the current evidence.

Selection of criteria for decision on adoption of a technology in the primary healthcare setting

The three CEOs of district hospitals unanimously agreed that disease severity, improvement in efficacy and effectiveness, and public health issues are important criteria for decision-making. All agreed on the economic impact of the intervention, affordability, and opportunity costs. Additionally, contextual factors such as the scope of the healthcare system, appropriate use of the intervention, and system capacity received a positive response from all.

The size of the affected population, or improvement in safety or tolerability, or historical and political context, or pressures from stakeholders or individuals, in the context surrounding healthcare intervention received two positive responses each. Respondents disagreed (2 to 1) on the importance of improvement in-patient reported outcomes and contextual criteria, such as priority of the population and equity of access as relevant decision criteria. The responses are shown in Table 2.
Table 2
Decision Criteria preferred by the hospital managers

| Domains/Criteria                          | Domains/Criteria                          | (Frequency) Y/N |
|-------------------------------------------|-------------------------------------------|-----------------|
| **Need for the intervention**             | Disease severity                          | (3)/(0)         |
|                                           | Size of affected population               | (3)/(0)         |
| **Outcomes of the intervention**          | Improvement of the effectiveness/efficacy | (2)/(0)         |
|                                           | Improvement safety / tolerability         | (3)/(0)         |
|                                           | Improvement patient-perceived health / patient-reported outcomes | (2)/(1) |
| **Type of benefit of the intervention**   | Interest towards public health            | (3)/(0)         |
|                                           | Type of clinical benefit                  | (3)/(0)         |
| **Economic impact of intervention**       | Impact on the budget                      | (3)/(0)         |
|                                           | Impact on other spending– other medical/ non-medical costs | (3)/(0) |
| **Contextual criteria**                   | Mandate and scope of healthcare system    | (3)/(0)         |
|                                           | Population priority and access            | (2)/(1)         |
|                                           | Common goal and specific interests        | (1)/(1)         |
| **Feasibility of contextual criteria**    | System capacity and appropriate use of intervention | (3)/(0) |
|                                           | Political / historical / cultural context | (1)/(1)         |
| **Opportunity Cost**                      | Opportunity costs and affordability       | (3)/(0)         |

**Collection of evidence from the four steps**

The evidence map (Table 3) illustrates the evidence collected from steps 3 and 4 in the methodology.
| Domain/Topics                  | Evidence mapping | Results                                                                                                                                 |
|-------------------------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| **Health Problem (CUR)**      |                  |                                                                                                                                            |
| - Target population           |                  | In 2016 18,683 perinatal deaths registered in RSA. Two-thirds of the death occurs within the antenatal period [L;Allanson 2015].         |
| - Target conditions           |                  | 30–50% of fetal deaths attributable to FGA [L;Gardosi 2013].                                                                             |
| - Current management of the   |                  | 25% of children born in LMIC are SGA [L;Katz 2013].                                                                                      |
|    conditions                 |                  | Third trimester screening (> 28 weeks gestation) is not recommended for low-risk pregnant women. The standard of care is to inspect and    |
| - Utilization                 |                  |    palpate the pregnant uterus and measurement of symphysis fundal height [L;CC;Guidelines for Maternity care in South Africa 2015].      |
|                               |                  | Women, classified as having low-risk pregnancies between 28 and 32 weeks’ gestation were screened for placental insufficiency using      |
|                               |                  |    Umbiflow™ [L;Nkosi 2019].                                                                                                             |
| **Description of technology (TEC)** |                  |                                                                                                                                            |
| - Features of the technology  | Technology: portable continuous wave Doppler Ultrasound provides an affordable easy-to-use device [L;CT] |                                                                                                                                            |
| - Regulatory status           | Umbiflow™ was developed under ISO 13485 medical quality system. Applications for CE Mark in process [L; CT] |                                                                                                                                            |
| - Investments required to use | Equipment & supplies needed: laptop, printer (paper), gel                                                                             |
|    the technology             | Access – patients coming to clinic/CHCs at > 28 weeks gestation with SFH 26-30cm (if gestational age unknown) [L; CC].                |
| - Training and information    | Patient approval necessary - consent form provided [UC; UM].                                                                         |
|    needed to use the technology | Training provided to midwives/nurse practitioners (non-specialist) to be used in primary-health care settings and antenatal clinics [UM; UC]. |
| **Safety (SAF)**              |                  |                                                                                                                                            |

L: Literature on health care system, legislation in the country, continuous wave Doppler ultrasound and Umbiflow™; CC: Clinician Consultation; CT: Technical Consultation; UM: User survey midwives and nurses; UC: User survey clinician; P: Patient; CW: continuous wave; PW: pulse wave; DUS: Doppler ultrasound; U: Umbiflow; CHC: Community Health Centres; ANC: antenatal care; CHW: community health worker; SAMRC: South African Medical Research Council; CSIR: Council of Scientific and Industrial Research
| Domain/Topics   | Evidence mapping                                                                                                                                                                                                 | Results                                                                                                                                                                                                                                                                                                                                 |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Patient safety | CW Doppler have lower output emissions in comparison to PW Doppler [CT;L; ECMUS].                                                                                                                                  | Even though the CW DUS is termed safe, exposure time (transducer) is advised to be kept as short as possible.                                                                                                                                                                                                                         |
|                |                                                                                                                                                                                                                   | There can be risk of error due to inexperience of user [UM; UC].                                                                                                                                                                                                                                                                               |
|                |                                                                                                                                                                                                                   | False negative rate was 1.3% and false-positive rate 9.0% [L; Nkosi 2019]. False positive rate lead to unnecessary hospital referrals and can lead to adverse outcome from unnecessary interventions, in case of false positives [L].                                                                                     |
|                |                                                                                                                                                                                                                   | Compared to current standard of care, use of Umbiflow™ may substantially reduce the prevalence of unexplained stillbirths in South Africa [L;UC;UM]                                                                                                                                     |

**Clinical Effectiveness (EFF)**

| - Mortality      | The women were screened for placental insufficiency in the unselected population under study. The prevalence of abnormal flow indices and absent end diastolic flow of the umbilical artery was higher in the population under study than recorded in higher income countries [L; Nkosi 2019]. The Umbiflow led to reduction in perinatal mortality rate. |
| - Morbidity      |                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                         |
| - Change-in-management |                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                         |
| - Benefit-harm balance | The RI was classified as low or high risk according to the value in relation to the RI graph [L; Pattinson 1989]. A cut-off of 75th percentile was used.                                                                        | SFH measurements and ordinary abdominal palpitations are used [CC], which is in accordance to the antenatal care policy [L;SA Maternal guideline 2015]. SF measurement is not effective in detecting small growth restricted babies, and it is as good or bad as ordinary palpation [CC;L;Cochrane systematic review 2017]. |
|                |                                                                                                                                                                                                                   | False positives can lead to unnecessary referrals to district hospital [L; Mufenda 2015].                                                                                                                                                                                                                                                 |

**Costs and economic evaluation (ECO)**

L: Literature on health care system, legislation in the country, continuous wave Doppler ultrasound and Umbiflow™; CC: Clinician Consultation; CT: Technical Consultation; UM: User survey midwives and nurses; UC: User survey clinician; P: Patient; CW: continuous wave; PW: pulse wave; DUS: Doppler ultrasound; U: Umbiflow; CHC: Community Health Centres; ANC: antenatal care; CHW: community health worker; SAMRC: South African Medical Research Council; CSIR: Council of Scientific and Industrial Research
| Domain/Topics | Evidence mapping | Results |
|---------------|------------------|---------|
| - Process related costs | | A cost analysis of introducing the technology in a CHC in South Africa was performed from a societal perspective [L: Chiwire 2015]. Calculation of cost per patient at a secondary level hospital from the patient's perspective and that of referrals from the health system perspective was conducted. The costs were found to be less, thus reducing the burden on secondary level hospital.

Another study on introduction of Umbiow in the clinical system, found that it would be cost-effective when comprehensive emergency obstetric care are also available [L; Rossouw 2017]. |

**Ethical impact (ETH)**

- Autonomy
- Legislation

As with other new technologies, the relative uncertainties in realization of the promise of the benefits have to balance against the psychological benefit of patients wanting to be informed about the well-being (in some cases the first time) of the foetus [L].

The utilization of the technology in remote areas widens access [UM]

**Organizational impact (ORG)**

- Health delivery process
- Management

The patient flow diagram shows that patient pathway when Umbiow™ is added to the standard of care [L;CC;Figure 2].

Currently, the patients are asked additionally if they would like to be screened using Umbiow. Consultation with clinician follows thereafter [CC]. The patients sign a consent form.

The nurses and midwife highlighted the need of regular communication between the staff of the CHC and those using Umbiow™ [UM;UC]. The nurses/midwives are provided with mandatory training on the use of Umbilow. They also pointed out that they found availability of space is limited due to sharing of examination rooms [UM;UC].

Technicians at CSIR are available when technology is malfunctioning [CC].

**Patient and social aspect (SOC)**

L: Literature on health care system, legislation in the country, continuous wave Doppler ultrasound and Umbiow™; CC: Clinician Consultation; CT: Technical Consultation; UM: User survey midwives and nurses; UC: User survey clinician; P: Patient; CW: continuous wave; PW: pulse wave; DUS: Doppler ultrasound; U: Umbiow; CHC: Community Health Centres; ANC: antenatal care; CHW: community health worker; SAMRC: South African Medical Research Council; CSIR: Council of Scientific and Industrial Research
Internationally pregnant women rate US as one of the most important aspects of their antenatal care [L; Molander 2010]

In this case, it was “only” a graphical and sonar presentation. The nurses at the CHCs mention that most pregnant women did not know how to connect with their unborn babies and were impressed about diagnosis and intervention before birth. They also needed the security of knowing that their baby is well [UM; UC].

The patients are encouraged by nurses/midwives come to subsequent visits and for ANC. However, there are always lost to follow-up. In some areas [L; Nkosi 2019], it has been observed that with visits of CHWs to the household, adherence was improved.

The patient have been found to enjoy the added attention, hearing the fetal heart and doppler sound wave. The high risk patients enjoy it the most because they also get to interact more with the staff. After birth, some women have visited the clinics and CHCs to show their newborn and other send pictures of their babies and thank you messages [UM; CC; P].

Legal impact (LEG)

- Autonomy of the patient
- Privacy of the patient

National Health Act Sect. 14 – confidentiality of patient’s health status [L]. The patients are asked to fill a consent form before the screening is conducted. The procedure, the result and its implication are explained to the patient.

The Protection of Personal Information (POPI) Act (No 4 of 2013) L: [POPI Act; Buys 2017] provides legal boundaries to safeguarding of patient information in daily practice.

During the current trial of Umbiow™ in the health care units, the acquisition contract entails liability sharing between CSIR/SAMRC and the respective health care unit.

In Step 3, a total of 65 relevant sources of evidence were collected following the search in bibliographic databases, expert consultation and hand searching the reference lists of already identified sources. The flow of information is documented in a PRISMA flowchart (see “Supplementary Fig. 1f, Additional File 1”).

For all domains, a combination of evidence from peer-reviewed and grey literature with expert input was necessary to complete the evaluation of Umbiow™. Evidence on the health problem and current use of the technology (CUR) was mainly obtained from global and local literature on maternal and child health (Step 3), supplemented by information provided during expert consultation (Step 4). Information on the
technical characteristics (TEC) of the DUS in general and Umbiflow™ in particular was retrieved from technical literature and in consultation with the experts; users (Step 4) provided information on training needs and characteristics. For safety (SAF), the expert consultation yielded additional details on usability and type of errors. Evidence on economics (ECO) was obtained from the completed Master’s thesis on cost analysis and a conference abstract (paper unpublished) on cost-effectiveness analysis, shared by the PI. The site visit described in the methodology (Step 4) gave further insight into communication requirement and patient acceptance of the technology. Information on legal matters (LEG) was difficult to obtain; the two acts mentioned in Table 3 provided important background information on safeguarding patient rights.

**Users’ experience on Umbiflow™**

The detailed responses provided by the nurse practitioners, midwives and clinicians through the survey questionnaire provided insight on the use of the Umbiflow™ for obstetric services in its intended setting in the South African health system. Eight nurses and six clinicians responded to the survey.

The nurses informed that utilization of these additional Doppler ultrasound services led to complications in work processes, misunderstandings and difficulties arising from having to share the examination rooms limiting privacy for patients. They recommended that trainees start using the device right after the training period to minimize reading errors. Computer literacy is mandatory, as sometimes assistance in dealing with computer malfunctioning can take time. They also pointed out the communication flow among doctors and nurses on duty at the centres should be maintained, as currently the technology is not included in the standard of care.

Clinicians welcomed an innovative solution, effective and low cost, addressing the need to prevent stillbirths. However, not all clinicians used it themselves. One of the clinicians perceived the use of Umbiflow™ as beneficial for patient care and early management. The technology had the potential to improve the current patient pathway by earlier recognition of fetus at risk for growth restriction at the local clinic level. Another clinician indicated that this could help in reduction of serious adverse events and resulting litigations. They were uncertain about the real cost of the technology when adopted into standard care and disagreed on the need for extra staff. A few suggested that the midwives currently employed could be trained on using the technology. A clinician stated that computer literacy is mandatory and another indicated that funding could be an influencing factor. Overall, they found that it would be beneficial at the PHC setting.

A mapping of the evidence according to the CM assessment elements is shown in Table 3.

**Evaluation of Umbiflow™**

The following sections summarize the best available evidence on Umbiflow™ for the primary care setting in South Africa. Diagnosis using continuous wave DUS was evaluated and compared with usual care i.e. non-use of DUS or other forms of US.

**Health problem and current use of the technology (CUR)**
In South Africa, unexplained fetal mortality is the largest single contributor to perinatal deaths [24]. A quarter of these fetuses are small for gestational age (SGA), two-thirds of these deaths occur during the last trimester of pregnancy [25]. At the public PHC level, Community Health Centres (CHCs) often include a clinic for the local catchment area, a referral section with specialists, and a 24 hours unit with maternity and casualty staff. Clinics draining into the Community Health Centres (CHCs) provide antenatal care for low and intermediate-risk women, including point of care blood and urine testing [26]. CHCs provide 24-hour comprehensive health service with an obstetric unit run by midwives.

Currently, Umbiow™ is used in the context of the ongoing cohort trials. After receiving their routine ANC visit, the women would be taken by the nurse or midwife to an examination room for the scan to be performed. The procedure of the examination is explained to the patient by either the nurse or the clinician present and the patient is asked to sign a consent form. Due to the high burden and abundant research, evidence on the health problem was readily available from the literature on maternal and child health care, as also highlighted in other studies [27]. However, information on the use of the technology was only forthcoming from experts involved in related trials.

**Description and technical characteristics (TEC)**

Umbiow™, is a continuous-wave DUS device for use at PHC facilities and antenatal clinics. The software processes the US signals to generate a high quality waveform depiction of the umbilical blood flow. The waveforms are displayed on the computer screen. The “resistance index” (RI) which can be directly linked to the functioning of the placenta [28] is calculated and plotted on a percentile chart against gestational age [29]. Regular training is provided to the staff using the technology. Evidence collated from the literature and in consultation with the clinicians and nurses underlined, the need of additional investments and mandatory training required to use the technology. Important services such as availability of maintenance contract, upgrade of software, regular technical analysis, and risk assessment are provided by CSIR. However, as the nurses indicated challenges such as power outage at the clinic, malfunctioning of the DUS or delay in live technical support, exists in practice.

**Safety (SAF)**

DUS can produce biological effects such as tissue heating representing a potential health risk. However, the continuous wave DUS have low output intensity in comparison to pulse wave Doppler [30]. Nonetheless, it is advised to keep exposure time as short as possible [10].

The potential disadvantages include false-positive and false-negative results, although these rates are typically low [28, 31]. If a false positive occurs, the patients are likely exposed to avoidable cost and anxiety, which may lead to inappropriate intervention [32]. The false negative cases may not be captured unless the clinical condition of the mother changed [31].

**Evidence on Clinical Effectiveness (EFF)**

Evidence on effectiveness of continuous-wave DUS was mainly obtained from literature, supplemented by information specifically on Umbiow™ obtained from consultation with experts and users. All studies
on Umbiflow™ were cohort studies, conducted in South Africa; randomized trials have not been conducted yet.

The studies on Umbiflow™ reported diagnosis related adverse events. Nkosi et al [28] determined the false-negative rate in a sample of 226 low-risk pregnant women, by using Umbiflow™ and re-tested with conventional ultrasound and pulsed Doppler. A false negative rate of 1.3% and specificity of 98.7% in this sub-set was obtained for Umbiflow™. The study had a sensitivity of 91%. The three women in the study attended the high-risk clinic for full assessment [28]. In this study, the false positive rate was 9.0% with a sensitivity of 91.0% for 32/355 high risk cases. These women were referred back to their local clinic to continue with their routine ANC.

In 2005, Theron et al [29] examined the effectiveness of the PC-based Umbiflow™ in relation to a well-known commercial standard system in a cohort study and found their accuracy to be comparable. Hugo et al [31] evaluated the use of Umbiflow™ by trained midwives at a secondary hospital to assess the umbilical artery velocity waveforms in high-risk pregnancy. It was initially aimed at reducing unnecessary referrals for pregnant women with fetuses, which were SGA [33]. Findings showed that this continuous-wave DUS was effective in screening low-risk pregnancies, identifying at-risk fetuses requiring interventions, and in reduction of additional tests arising from false negative results [28].

Timely detection of abnormalities in the blood flow in the uterine artery followed by management of undiagnosed placental insufficiency could lead to prevention of perinatal deaths [6, 28, 34]. Appropriate management will depend on the severity and the gestation of the pregnancy. When it first presents at later stages of pregnancy (at 34 weeks), a scheduled C-section is a necessary action. As this can occur preterm, added risk of mortality and morbidity arises. Currently, no effective antenatal therapy exists for fetal growth restriction; hence, delivery could be the only viable option [35]. A recent study observed a 1.5% prevalence of absent end diastolic flow (AEDF), a sign of fetal vascular stress, in a population of low-risk pregnancies, indicating that using the Doppler RI information in the study population reduced the rate of macerated stillbirth by 60% [28, 34].

**Economic impact – costs and resources used (ECO)**

The evidence for economic impact of use of DUS in a clinical setting was taken (see Section on evidence retrieval, above) from grey literature. Rossouw et al. [36, 37] showed that introducing Umbiflow™ in South Africa would be cost-effective only with concurrently available comprehensive emergency obstetric care. They found the use for testing placental insufficiency to be more cost-effective than other interventions such as therapeutic feeding or antiretroviral treatment or new vaccine in South Africa [34]. Chiwire [32] performed a cost analysis of introducing Umbiflow™ in a community health centre in South Africa from a societal perspective and included consumables, personnel costs, and costs such as opportunity costs arising from visiting healthcare facilities. The study undertook calculation of cost per patient at a secondary level hospital from the patient’s perspective and referrals from the health system perspective. The societal cost at the PHC setting was approximately 3 times less than that at the secondary hospital, reducing the burden on secondary level health system.
Organizational Aspects (ORG)

The literature on Umbiflow™ and consultation with the users and experts provided evidence on organizational aspects. Healthcare professionals including nurses or midwives can use the device after receiving short training to detect correct soundwave and visually interpret a correct wave pattern on the computer screen [33]. The learning curve is dependent on image interpretation and acquisition skills. Since the midwives or nurse practitioners receive a few days of mandatory training initially, the curve shows an early rise, followed by a plateau.

Information provided from current users of the technology in South Africa suggests that they sometimes lack resources to provide services in informative and proper manner (blood pressure monitor, furniture, scale, poor network connection, power shortage etc.). Additional infrastructure, such as extra examination room, is not required due to the portability feature of the machine, and screening can be integrated within the organizational infrastructure associated with standard of care (see Fig. 2). However, this may not be always ideal due to a lack of privacy and insufficient hygiene conditions. Active interaction and communication between the routine clinic staff and health professionals using Umbiflow™ would ease organizational challenges. Nurses interviewed for this study suggested sensitization on the benefit of using Umbiflow™ among health professionals and the patient and caregiver through workshops or information days.

Legal Aspects (LEG)

Section 14 of the National Health Act [14, 38] of South Africa states the information relating to the patient’s health status is confidential. It further specifies that patients have to actively consent to any disclosure of their information. In the study setting, patients fill a consent form, the Umbiflow™ procedure, the result and its implications are explained to them. The Protection of Personal Information Act (No 4 of 2013) [39] provides legal boundaries to safeguard patient information in daily practice. No further legal implications of the introduction of Umbiflow™ could be identified.

Ethical Aspects (ETH)

The evidence on ethical aspect of using Umbiflow™ was extracted from literature on DUS. The use of Umbiflow™ is expected to lead to detection of anomalies in the third trimester. As with other ultrasounds, the relative uncertainties in realization of the promise of the benefits have to balance the psychological benefit of patients wanting to be informed about the well-being (in some cases the first time) of the fetus. This subjective benefit must be weighed against inconvenience of situations leading to unneeded referral to a district hospital or can lead to adverse outcome from unnecessary interventions, in case of false positives. The DUS screening is done only with patient consent. Not all pregnant women visiting the clinics are willing to be screened, which could be due to religious, cultural, or spiritual beliefs [40–42].

Patient and Social Aspects (SOC)
Patients are required to provide their consent before Umbiow™ examination. Nurses at the CHCs confirmed that patients favoured the technology. They stated that, most patients were not knowledgeable on how to care for their unborn babies (e.g. intake of nutrients) and connect with them. The patients were impressed about the possibility of diagnosis and intervention before birth and some wished for an examination.

**Discussion**

This study reports on the value of stakeholder engagement and consultation during scoping evidence. It tests the feasibility of using the EUnetHTA Core Model in a non-European country to assess the technology for adoption in low resourced PHC setting.

First, consensus was sought on the relevancy of the HTA CM domains and the guided questions. Briefly, the domains, CUR and SAF and three others, EFF, ETH and SOC had received a median of 5 and 4 respectively and a narrow IQR (4,5). The result of the ranking led to four other domains having a wider IQR (≥>3.4,5). Since some of the issues within these domains had a narrower IQR, these issues were considered. Since the model has 134 assessment elements, the final number selected was smaller, and the scope was more targeted. As with other adaptations, few of the issues were rearranged as they were viewed suitable in a different domain [43].

The scoring could have been influenced by the fact that the health services are free of charge for maternal, child healthcare and procurement and financial administration of PHC falls under district health office. Consensus was reached with a wider IQR (e.g. 3 to 5) for the evidence needed for organizational or legal aspects, as well as technical characteristics. This may be because the expression “technical characteristics,” is misleading for decision-makers. Due to the newness of the HTA concept and the CM among these stakeholders, misunderstanding and misjudgment of the selection could have resulted in error in the ranking of the domains and the respective AEs.

Second, this work sought to understand the decision process for procurement of the technology (i.e. hospital CEO). Generalization of the decision criteria is not possible at this stage as only three hospital managers responded to the questionnaire; however, their informational needs seem to be largely covered by the domains prioritized in this study. The AdHopHTA (Adopting hospital-based HTA) project, which is a European Project on hospital-based HTA aims to promote collaboration of hospital-based HTA initiatives. Unlike the recommendation given in the AdHopHTA guideline [44] consensus on the impact of political and strategic aspect of adoption of the technology was not reached. It is noteworthy that while the district health managers were uncertain about the relevance of organizational aspects, such as system capacity and appropriateness, both hospital CEOs and Umbiow™ operators highlighted their significance. This further supports the main hypothesis of this study, namely that involving a broad range of stakeholders is crucial for understanding the scope of necessary evidence for informed decision-making.
Third, the inclusion of experts and users of the technology in a standardized manner in the evidence scoping process reduced the gaps in identified evidence, adding to the understanding of the appropriateness, acceptability, accessibility, and perceived affordability of the technology in its intended setting of application.

Fourth, the synthesis of collected evidence shows that screening using continuous-wave DUS may be better suited than only SFH measurements in detecting pregnancies at risk of stillbirth. Heazell et al [45] in their study on economic and psychosocial consequences of stillbirth concluded that even though costs of stillbirth prevention is high, the combined direct, indirect and intangible costs are higher. WHO in its ANC guideline calls for low-cost and accurate screening tool for detecting abnormal fetal growth in LMICs [6]. Yet, a recent study of two-stage routine conventional ultrasound screening in LMICs detected no effect of screening on stillbirth prevention [7, 46]. This seriously questions the role of conventional ultrasound screening for prevention of stillbirths and calls for a randomized trial using Umbiow™ to confirm its role in detection of at-risk pregnancies. The Department of Health of South Africa is supporting a project to implement Umbiow™ as a routine screening tool for ANC.

**Strengths And Limitations**

The assessment carried out in this study demonstrates the promise of Umbiow™ in context by drawing on additional, qualitative judgments on the functioning of the device, its proposed benefits, and the plausibility that its adoption will provide the claimed improvements. To mitigate uncertainty in the absence of robust randomized control trials, experts were consulted, and stakeholders involved, which aided the assessment process. However, it is important to reiterate the limitations of expert opinion as evidence for HTA, given its substantial potential for bias.

Involving the decision-makers on the ranking of the domains and the criteria for assessment sensitized them on the usefulness of CM and their acceptance on the relevancy of the evidence. The necessity of broader upstream consideration, besides, cost-effectiveness early on in the technology lifecycle [47] can contribute to the sustainability of the health system.

One of the advantage of Umbiow™ is that an experienced sonographer is not needed. However, skill levels and scanning method may differ between the operators and may need the intervention of the clinician on duty. However, use is simple for the nurses and they could master the techniques within short time.

The selection of assessment domains and elements based on deliberation is challenging due to the diversity of user demands and preferences. Furthermore, none of the district managers and hospital decision makers involved in this study requested further clarifications or information. It is therefore uncertain how these stakeholders interpreted the description of the individual AEs. Due to the complexity and newness of the CM, some respondents may have misunderstood and not selected certain relevant AEs.
Since 2005, further development and improvement of the technology incorporating latest mobile and information technologies, software development has taken place. However, no studies have compared previous models to the current models and therefore it is unclear whether results obtained from previous models are generalizable to the model currently under study.

This study did not consult gynecologists who are unfamiliar with DUS or do not work in the PHC setting. They could have provided their perspective on the benefit of a DUS to be used at the PHC level.

Involvement of the research institute funding the project may have the potential for introducing bias in the reporting of outcomes.

Conclusion

This study tested the applicability of the HTA CM to evaluate the value of a technology before adoption in a low-resource setting. Mapping a set of decision criteria before the assessment process addressed the perceived gaps in evidence. Collection and generation of evidence based on the HTA CM and the chosen decision criteria provided a generalized but structured guidance on the methodology. Several issues did not apply for the technology and the context of its use. To streamline the issues and thus the assessment elements, careful appraisal and application to other classes of MDs to eliminate those that do not fit into the African context will be required.

The study thus highlighted the potential organizational impact and clinical benefit of a simple low-cost technology, such as the continuous-wave DUS, in a primary care setting. Further robust evidence will be essential to determine the future of this technology, which is competing with similar innovative technology.

Engaging and consulting stakeholders locally was imperative to understand the context, reduce evidence gaps and address the uncertainties in the evidence, ultimately paving the way for technology adoption. The consideration of risks associated with the technology use and its low cost need to be balanced with the acceptance and the promise of the technology in the context. The transparency in assessment process and method is vital, as the assessment involved experience and elements of judgement.

Abbreviations

AEDF
Absent end diastolic flow
AE
Assessment element
ANC
Antenatal care
CEO
Chief executive officer
CHC
Community health centre
CM
Core Model
CSIR
Centre for Scientific and Industrial Research
CUR
Health problem and current of use of technology
DUS
Doppler ultrasound
ECO
Economic impact
EFF
Clinical effectiveness
ETH
Ethical aspects
EUnetHTA
European Network for Health Technology Assessment
EVIDEM
Evidence and Value:Impact on Decision making
HTA
Health Technology Assessment
IQR
Interquartile range
LEG
Legal aspects
LMICs
Low- and middle- income countries
MD
Medical device
ORG
Organizational aspects
PHC
Primary healthcare
PI
Principal investigator
RI
Resistance index
SAF
Safety
Declarations

Ethics Declarations:

Ethics approval and consent to participate: Ethics approval was not required as the activity was component of a larger programme evaluation.

Consent for publication: Not applicable

Availability of data and materials: The data used in this evaluation are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests

Funding: None

Authors’ contribution: DM contributed to the conception and design of the study, acquisition and interpretation of the data, drafted and finalized the manuscript. RP and TMH facilitated data collection. DP contributed to critical inputs during the manuscript drafting and supervised the work. The authors reviewed the draft and approved the final version of the manuscript.

Acknowledgement: A special thank you is extended to all the nurses, midwives and clinicians who responded to the survey.

References

1. You D, Hug L, Ejdemyr S, Idele P, Hogan D, Mathers C, et al. Global, regional, and national levels and trends in under-5 mortality between 1990 and 2015, with scenario-based projections to 2030: A
systematic analysis by the UN Inter-Agency Group for Child Mortality Estimation. Lancet. 2015;386:2275–86. doi:10.1016/S0140-6736(15)00120-8.

2. WHO. Trends in maternal mortality 2000 to 2017: estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division. Geneva:WHO; 2019. https://www.who.int/reproductivehealth/publications/maternal-mortality-2000-2017/en/.

3. Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, et al. Stillbirths: Rates, risk factors, and acceleration towards 2030. Lancet. 2016;387:587–603.

4. Manasyan A, Saleem S, Koso-Thomas M, Althabe F, Pasha O, Chomba E, et al. Assessment of obstetric and neonatal health services in developing country health facilities. Am J Perinatol. 2013;30:787–94.

5. Kruk ME, Kujawski S, Moyer CA, Adanu RM, Afsana K, Cohen J, et al. Next generation maternal health: external shocks and health- system innovations. Lancet. 2016;388:2296–306.

6. WHO. World Health Organization recommendations on antenatal care for a positive pregnancy experience. Geneva:WHO; 2016.

7. Goldenberg RL, Nathan RO, Swanson D, Saleem S, Mirza W, Esamai F, et al. Routine antenatal ultrasound in low- and middle-income countries: first look – a cluster randomised trial. BJOG An Int J Obstet Gynaecol. 2018;125:1591–9. doi:10.1111/1471-0528.15287.

8. Kim ET, Singh K, Moran A, Armbruster D, Kozuki N. Obstetric ultrasound use in low and middle income countries: A narrative review. Reprod Health. 2018;15:1–26. doi:10.1186/s12978-018-0571-y.

9. Baj N, Dubbins P, Evans JA. Obstetric ultrasound education for the developing world: A learning partnership with the World Federation for Ultrasound in Medicine and Biology. Ultrasound. 2015;23:53–8. doi:10.1177/1742271X14566848.

10. Nicolaides K, Rizzo G. Doppler in Obstetrics. In: Placental and Fetal Doppler. CRC Press; 2002. https://fetalmedicine.org/var/uploads/Doppler-in-Obstetrics.pdf.

11. 10.1002/14651858.CD007529.pub4
    Alfirevic Z, Stampalija T, Dowswell T. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database Syst Rev. 2017, Issue 6. Art No.: CD007529. doi:10.1002/14651858.CD007529.pub4.

12. WHO. Standards for improving quality of maternal and newborn care in health facilities. Geneva:WHO; 2016.

13. WHO. Primary Health Care Systems (Primasys): Case Study in South Africa. Geneva:WHO; 2017.

14. Hassim A, Heywood M, Berge J. The statutory and administrative framework of the public health system. In: Health and Democracy:A guide to human rights, health law and policy in post-apartheid South Africa. 2007; 520. http://section27.org.za/2007/06/health-and-democracy/.

15. Pillay Y, Barron P. The implementation of PHC re-engineering in South Africa. Public Health Association of South Africa. 2012;1–6. Available from: http://www.phasa.org.za/articles.
16. Mueller D. Addressing the challenges of implementing a Health Technology Assessment Policy framework in South Africa. Int J Technol Assess Health Care. 2020;1–6. doi:10.1017/S0266462320000562.

17. Lampe K, Mäkelä M, Garrido MV, Anttila H, Autti-Rämö I, Hicks NJ, et al. The HTA Core Model: A novel method for producing and reporting health technology assessments. Int J Technol Assess Health Care. 2009;25(SUPPL.S2):9–20.

18. National Department of Health SA. Presidential Health Summit Compact. 2018; June.

19. Mueller D, Tivey D, Croce D. Health-technology assessment: Its role in strengthening health systems in developing countries. S Afr J Public Health. 2017;2:6–11. doi: 10.7196/SHS.2017.v2i1.50.

20. O’Donnell JC, Pham SV, Pashos CL, Miller DW, Smith MD. Health technology assessment: Lessons learned from around the world - An overview. Value Heal. 2009;12 SUPPL. 2:S1–5. doi:10.1111/j.1524-4733.2009.00550.x.

21. Croce D, Mueller D, Tivey D. Challenges and limitations to adopting health- technology assessment in the South African context. S Afr J Public Health. 2017;2:26–9. doi: 10.7196/SHS.2017.v2.i2.58.

22. European network of HTA. EUnetHTA Joint Action 2, Work Package 8. HTA Core Model ® version 3.0 (Pdf); 2016.

23. Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Evidence and Value: Impact on DEcisionMaking - The EVIDEM framework and potential applications. BMC Health Serv Res. 2008;8:1–16.

24. Madhi SA, Briner C, Maswime S, Mose S, Mlandu P, Chawana R, et al. Causes of stillbirths among women from South Africa: a prospective, observational study. Lancet Glob Heal. 2019;7:e503–12. doi:10.1016/S2214-109X(18)30541-2.

25. Allanson ER, Muller M, Pattinson RC. Causes of perinatal mortality and associated maternal complications in a South African province: Challenges in predicting poor outcomes. BMC Pregnancy Childbirth. 2015;15:1–7.

26. National Department of Health Republic of South Africa. Guidelines for Maternity Care in South Africa. A manual for clinics, community health centres and district hospitals. South African Gov. 2015;1–174. doi:10.4028/www.scientific.net/AMR.1010-1012.610.

27. Hollingworth S, Downey L, Ruiz F, Odame E, Dsane-Selby L, Gyansa-Lutterodt M, et al. What do we need to know? Data sources to support evidence-based decisions using health technology assessment in Ghana. Heal Res Policy Syst. 2020;8:1–12.

28. Nkosi S, Makin J, Hlongwane T, Pattinson RC. Screening and managing a low-risk pregnant population using continuous-wave Doppler ultrasound in a low- income population: A cohort analytical study. S Afr Med J. 2019;109:347–52.

29. Theron GB, Theron AM, Odendaal HJ. BA. Comparison between a newly developed PC-based Doppler umbilical artery waveform analyser and a commercial unit. S Afri Med J. 2005;95.
30. European Committee of Medical Ultrasound Safety. Clinical Safety Statement for Diagnostic Ultrasound. Ultraschall der Medizin -. Eur J Ultrasound. 2006;29:98–9.

31. Hugo EJC, Odendaal HJ, Grove D. Evaluation of the use of umbilical artery Doppler flow studies and outcome of pregnancies at a secondary hospital. J Matern Neonatal Med. 2007;20:233–9.

32. Chiwire P. Maternal, Health: Cost analysis of introducing the umbiflow velocity doppler system at primary health level. Master’s thesis. University of Cape Town. 2015.

33. Mufenda J, Gebhardt S, Van Rooyen R, Theron G. Introducing a mobile-connected umbilical doppler device (UmbiFlow™) into a primary care maternity setting: Does this reduce unnecessary referrals to specialised care? Results of a pilot study in Kraaifontein, South Africa. PLoS One. 2015;10:1–13.

34. Pattinson RC, Hlongwane TMAG, Vannevel V. Challenges to improve antenatal and intrapartum care in South Africa. S Afr Med J. 2019;109:15–9.

35. Malhotra A, Allison BJ, Castillo-Melendez M, Jenkin G, Polglase GR, Miller SL. Neonatal morbidities of fetal growth restriction: Pathophysiology and impact. Front Endocrinol (Lausanne). 2019;10 FEB:1–18.

36. Rossouw L, Spencer NPR. Cost-effectiveness of the Umbiflow Doppler to screen and manage a low-risk pregnant population in a middle-income country. 2017.

37. Rossouw L, Nkosi SPR. Cost-effectiveness of Umbiflow Doppler to screen and manage a low risk pregnant population in a middle-income country. In: Priorities in Perinatal Care Conference. Mpekweni Beach Resort, Eastern Cape, South Africa.

38. National Department of Health Republic of South Africa. The National Health Act No 61 of 2003. Gov Gaz. 2004;469:1–94. doi:102GOU/B.

39. Buys M. Protecting personal information: Implications of the protection of personal information (POPI) act for healthcare professionals. S Afr Med J. 2017;107:954–6.

40. Lincetto O, Mothebesoane-Anoh S, Gomez PMS. Antenatal care. Rev Inrm. 2012;:45–6.

41. Gopichandran V, Subramaniam S, Kalsingh MJ. Psycho-social impact of stillbirths on women and their families in Tamil Nadu, India - a qualitative study. BMC Pregnancy Childbirth. 2018;18:1–13.

42. Finlayson K, Downe S. Why Do Women Not Use Antenatal Services in Low- and Middle-Income Countries? A Meta-Synthesis of Qualitative Studies. PLoS Med. 2013;10.

43. Radaelli G, Lettieri E, Masella C, Milano P, Merlino L, Strada A, et al. Implementation of Eunethta Core Model in Lombardia: The VTS Framework. Int J Technol Assess Health Care. 2014;(30):1–8. doi:10.1017/S0266462313000639.

44. Sampietro-Colom L, Lach K, Cicchetti A, Kidholm K, Pasternack I, Fure B, Rosenmoller M, Wild C, Kahveci R, Wasserfallen JB, Kiivet RA, et al.sampietro-Colom L, Lach K, Cicchetti A, Kidholm K, Pasternack I, Fure B, Rosenmoller M, Wild C, Kahveci R, Wasserfa et al The AdHopHTA handbook: a handbook of hospital–based Health Technology Assessment (HB–HTA); Public deliverable; The AdHopHTA Project (FP7/2007–13 grant agreement nr 305018). 2015.
Heazell AEP, Siassakos D, Blencowe H, Burden C, Bhutta ZA, Cacciarelli J, et al. Stillbirths: Economic and psychosocial consequences. Lancet. 2016;387:604–16.

10.1002/14651858. CD001450.pub4

Alvirevic Z, Stampalija T, Medley N. Fetal and umbilical Doppler ultrasound in normal pregnancy. Cochrane Database Syst Rev. 2015, Issue 4. Art. No.: CD001450. doi: 10.1002/14651858. CD001450.pub4.

Lehoux P, Roncarolo F, Silva HP, Boivin A, Denis JL, Hébert R. What health system challenges should responsible innovation in health address? Insights from an international scoping review. Int J Heal Policy Manag. 2019;8:63–75. doi:10.15171/ijhpm.2018.110.

Figures

Figure 1

The data collection and extraction for HTA of the UmbiflowTM
Figure 2

Legend: Patient pathway on introduction of UmbiflowTM into the clinical system in South Africa. Adopted from Nkosi et al. 2019 [28].

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- AdditionalFile1.docx